Pavel Hradil

This inventor holds 7 USPTO granted patents and 2 published patent applications and 4 EPO patents. Top assignees: Farmak, A.s., Hameln Pharma Plus Gmbh. Active years: 2006-2016.

USPTO Granted Patents = 7 (Patent Applications = 2)

% Patents Active = 42.9

EPO Patents = 4 (Patent Applications = 4)

Average Co-Inventor Count = 5.0

ph-index = 2

Forward Citations = 6(Granted Patents)

Location History:

Bohunovice, CZ (2006)
Hlusovice, CZ (2011 - 2016)

Company Filing History:

Hameln Pharma Plus Gmbh

patent

Years Active: 2006-2016

Loading Chart...

7 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9447120 - Crystalline forms of zinc trisodium pentetic acid (2016-09-20),

2. 9441006 - [object Object] (2016-09-13),

3. 8933250 - Process for the preparation of N-(1-benzo[b]thien-2-ylethyl)-N-hydroxyurea (2015-01-13),

4. 8487113 - Method for the preparation of tizanidine hydrochloride (2013-07-16),

5. 8129421 - Method for preparing 4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]-benzoic acid (2012-03-06),

6. 8034805 - Methods for the preparation of salts of 2-[2-(4-dibenzo[B,F][1,4]thiazepin-11-yl-1-piperazinyl)ethoxyl]ethanol (quetiapine) and for the purification thereof (2011-10-11),

7. H0002154 - Process for preparing R- and S-isomers of (R)-5-(2-( (2-(2-ethoxyphenoxy)ethyl)amino)propyl)-2-methoxybenzenesulfonamide (2006-04-03),

Title: Pavel Hradil: Innovator in Pharmaceutical Chemistry

Introduction

Pavel Hradil is a notable inventor based in Hlusovice, Czech Republic. He has made significant contributions to the field of pharmaceutical chemistry, holding a total of 7 patents. His work primarily focuses on the development of innovative compounds and methods that enhance medical imaging and treatment.

Latest Patents

Among his latest patents, one notable invention is related to the production of crystalline forms of zinc trisodium pentetic acid (Zn-DTPA). This invention aims to improve the efficacy of this compound in various medical applications. Another significant patent involves a compound known as 2-[4-[(methylamino)carbonyl]-1H-pyrazol-1-yl]adenosine, which serves as a selective A2A adenosine receptor agonist in myocardial imaging. This new polymorph, designated as polymorph E, is characterized by a specific X-ray diffraction pattern and a distinct DSC scan, showcasing its unique properties.

Career Highlights

Pavel Hradil has worked with reputable companies in the pharmaceutical industry, including Farmak and Hameln Pharma Plus GmbH. His experience in these organizations has allowed him to refine his skills and contribute to groundbreaking research and development in the field.

Collaborations

Throughout his career, Pavel has collaborated with esteemed colleagues such as Lubomir Kvapil and Martin Grepl. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas.

Conclusion

Pavel Hradil's contributions to pharmaceutical chemistry through his patents and collaborations highlight his role as a significant innovator in the field. His work continues to impact medical imaging and treatment methodologies, showcasing the importance of innovation in healthcare.